<DOC>
	<DOCNO>NCT01299597</DOCNO>
	<brief_summary>The present study investigate human enzyme inhibition effect SB-649868 CYP3A4 , use Simvastatin Atorvastatin CYP3A4 probe substrate , administer single dos : alone , two different occasion repeat dos SB-649868 , time SB-649868 2h SB-649868 .</brief_summary>
	<brief_title>A Single-centre Open Label Study Investigate Effect Repeat Doses SB-649868 Pharmacokinetics Simvastatin Atorvastatin Healthy Male Volunteers .</brief_title>
	<detailed_description />
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>1 . Healthy male subject , determine responsible experienced physician , base medical evaluation include medical history , physical examination , neuropsychiatric status use MINI International Neuropsychiatric Interview , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . However , Subjects cTpn I value 99th percentile normal range select assay always exclude enrollment ; Subjects alkaline phosphatase bilirubin &gt; 1.5xULN always exclude ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) ; 2 . Male 18 65 year age inclusive , time signing informed consent . 3 . Body weight ≥50 kg BMI within range 18.529.9 kg/m2 inclusive . 4 . Subjects must agree use one contraception method list protocol . This criterion must follow time first dose study medication 3 day post last dose ( equivalent 5 terminal halflives postlast dose ) . 5 . Having give write informed consent , include compliance requirement restriction list consent form . 1 . History presence significant psychiatric neurological , musculoskeletal , respiratory , gastrointestinal , hepatic , uncontrolled hypothyroidism . pancreatic renal disease condition know interfere absorption , distribution , metabolism excretion drug . 2 . Subjects , Investigator 's judgement , pose significant suicide risk . Evidence serious suicide risk may include history suicidal behaviour and/or suicidal ideation type 4 5 CSSRS last 6 month . 3 . History cardiovascular disease and/or evidence repolarization defect . 4 . Family history heriditary muscular disorder . 5 . Subjects abnormal ECG define : average QTcB QTcF &gt; 450 msec ; PQ &lt; 120 m &gt; 220 m ; complete leave bundle branch block ; secondor thirddegree AV block ; relevant ST/T wave abnormality ; atrial ventricular arrhtymias clinical significance determine Investigator . 6 . History regular alcohol consumption within 6 month study define : • average weekly intake great 21 unit ( 14 unit female ) average daily intake great 3 unit ( 2 unit female ) . 1 unit equivalent halfpint ( 220mL ) beer 1 ( 25ml ) measure spirit 1 glass ( 125ml ) wine . 7 . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . 8 . Vulnerable subject , subject mentally legally incapacitate , language barrier preclude adequate understanding cooperation . 9 . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen 10 . A positive test HIV antibody . 11 . A positive prestudy drug/alcohol screen . 12 . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . 13 . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . 14 . Consumption broccoli , radish sprout , cauliflower , cabbage , orange juice , apple juice grapefruit juice grapefruit within 7 day prior first dose study medication collection final pharmacokinetic blood sample . 15 . The subject participate clinical trial receive investigational product ( IP ) within follow time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect IP ( whichever longer ) . 16 . Exposure four new chemical entity ( i.e. , medical drug development ) within 12 month prior first dose day . 17 . Where participation study would result donation blood blood product excess 500 mL within 56 day period . 18 . Unwillingness inability follow procedure outline protocol . 19 . The subject unable unwilling abstain strenuous physical activity 48 h screen follow visit . 20 . Subject investigator his/her deputy , research assistant , pharmacist , study coordinator , staff relative thereof involve conduct study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>repeat dose</keyword>
	<keyword>statin</keyword>
	<keyword>safety tolerability</keyword>
	<keyword>drug interaction</keyword>
	<keyword>sb649868</keyword>
	<keyword>healthy male subject</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>